Curasight strengthened the development of its integrated uPAR-based platform during the third quarter of 2025. The company received EMA approval to initiate its first clinical study with its therapeutic radiopharmaceutical in aggressive brain cancer, while patient recruitment gained traction in the ongoing phase II study with its diagnostic platform. After the period Curasight announced further momentum in its pipeline, with the initiation of recruitment in the first clinical study investigating the company’s therapeutic platform uTREAT®. BioStock reached out to CEO Ulrich Krasilnikoff for comments.

Read the full article at biostock.se:
https://biostock.se/en/2025/11/curasight-avancerar-inom-bade-diagnostik-och-terapi-under-q3/
This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

Curasight

Senast

6,46

1 dag %

5,90%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån